Download our whitepaper,

"Enhancing Success in Panic Disorder Clinical Trials: From FDA Approvals to Improved Protocols"

Enhancing success in panic disorder

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Panic Disorder Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Panic Disorder.
  • Comprehensive Analysis of FDA-Approved Panic Disorder Drugs.
  • How Diagnostic Criteria for Panic Disorder Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Panic Disorder Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

Panic Disorder

Panic Disorder represents a significant and complex subset of anxiety disorders, characterized by recurrent and unexpected panic attacks that can severely disrupt daily life.

This whitepaper delves into the evolving understanding, prevalence, and treatment approaches for Panic Disorder, underpinned by a synthesis of the latest research and clinical insights. It explores the biological, psychological, and environmental factors contributing to the disorder, highlighting the challenges in its diagnosis and management.

With approximately 2.7% of U.S. adults affected annually and a notable global prevalence, this condition demands attention from healthcare providers, researchers, and policy makers. The report examines the advancements in therapeutic interventions, from first-line pharmacological options to evidence-based psychotherapies, as well as emerging clinical trials and market trends in treatment options. It also identifies the pivotal endpoints and challenges that continue to shape research and regulatory strategies in this field.

At iNGENū, we are dedicated to advancing the understanding and treatment of Panic Disorder. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.

Panic disorder affects approximately

2.5%

of the global population

 

Women are

2x

as likely as men to be diagnosed with Panic Disorder

 

The global market for Panic Disorder treatments was valued at USD

$9.7b

in 2023



Our clinical team has over

120

years of combined clinical trial experience